Biotech startup Immunai earns unicorn status with $215 million Series B
27.10.21 | Meir Orbach
This site uses cookies to ensure the best viewing experience for our readers.
Immunai
4 stories about Immunai
“The intersection of machine learning and biology is the future, and we want to be one of the first companies really helping push that forward.”
08.06.21 | CTech
Viola Ventures is Seeking Technologies that Combine AI and Fundamental Scientific Disciplines
02.06.20 | Allon Sinai
Immunai Announces $20 Million Seed Round to Fund Immune System Mapping
14.05.20 | Hagar Ravet
Tag does not exist. Please try again.